Evidence map›Paper›PMID 24253313›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2014

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus.

Xiaohong Li, Patricia C Galipeau, Thomas G Paulson, Carissa A Sanchez, Jessica Arnaudo, Karen Liu, Cassandra L Sather, Rumen L Kostadinov, Robert D Odze, Mary K Kuhner and 5 more

Open access · greenAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 152 citations in OpenAlex.

  1. Trial
  2. Biomarker Use in Barrett's Esophagus Surveillance.The American journal of gastroenterology · 2026
    Review
  3. Current Concepts for Diagnosing Non-Dysplastic and Dysplastic Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026
    Review
  4. Article
  5. Review
  6. Molecular Pathology of Gastroesophageal Cancer.Clinics in laboratory medicine · 2024
    Review
  7. Review
  8. Article
  9. Cancer Risk in Barrett's Esophagus: A Clinical Review.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Molecular Pathology of Gastroesophageal Cancer.Surgical pathology clinics · 2021
    Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Xiaohong LiDivisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024. bjr@fhcrc.org.
Patricia C Galipeau
Thomas G Paulson
Carissa A Sanchez
Jessica Arnaudo
Karen Liu
Cassandra L Sather
Rumen L Kostadinov
Robert D Odze
Mary K Kuhner
Carlo C Maley
Steven G Self
Thomas L Vaughan
Patricia L Blount
Brian J Reid
Fred Hutch Cancer Center · USUniversity of California, San Francisco · USUniversity of Washington · USCancer Research Center · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAJohns Hopkins University · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
PHYLOGENIES of Barrett's Esophagus LineagesP01CA091955 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY · 2002 to 2019
$35.9M
Modeling Neoplastic Progression in Barrett's Esophagus - Renewal -2R01CA140657 · NCI · WISTAR INSTITUTE · PI Carlo Maley · 2009 to 2026
$5.0M
ESTABLISHED INVESTIGATOR AWARD IN CANCER PREVENTION AND CONTROLK05CA124911 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI VAUGHAN, THOMAS L · 2007 to 2016
$1.6M
Predictors of Progression from Barrett's Esophagus to esophageal adenocarcinomaRC1CA146973 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI REID, BRIAN J · 2009 to 2010
$998k
NCI NIH HHS K05 CA124911NCI NIH HHS K05CA124911NCI NIH HHS P01 CA091955NCI NIH HHS P01CA091955NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA140657NCI NIH HHS RC1 CA 146973NCI NIH HHS RC1 CA146973
6 · The paper itself

Abstract

All cancers are believed to arise by dynamic, stochastic somatic genomic evolution with genome instability, generation of diversity, and selection of genomic alterations that underlie multistage progression to cancer. Advanced esophageal adenocarcinomas have high levels of somatic copy number alterations. Barrett's esophagus is a risk factor for developing esophageal adenocarcinoma, and somatic chromosomal alterations (SCA) are known to occur in Barrett's esophagus. The vast majority (∼95%) of individuals with Barrett's esophagus do not progress to esophageal adenocarcinoma during their lifetimes, but a small subset develop esophageal adenocarcinoma, many of which arise rapidly even in carefully monitored patients without visible endoscopic abnormalities at the index endoscopy. Using a well-designed, longitudinal case-cohort study, we characterized SCA as assessed by single-nucleotide polymorphism arrays over space and time in 79 "progressors" with Barrett's esophagus as they approach the diagnosis of cancer and 169 "nonprogressors" with Barrett's esophagus who did not progress to esophageal adenocarcinoma over more than 20,425 person-months of follow-up. The genomes of nonprogressors typically had small localized deletions involving fragile sites and 9p loss/copy neutral LOH that generate little genetic diversity and remained relatively stable over prolonged follow-up. As progressors approach the diagnosis of cancer, their genomes developed chromosome instability with initial gains and losses, genomic diversity, and selection of SCAs followed by catastrophic genome doublings. Our results support a model of differential disease dynamics in which nonprogressor genomes largely remain stable over prolonged periods, whereas progressor genomes evolve significantly increased SCA and diversity within four years of esophageal adenocarcinoma diagnosis, suggesting a window of opportunity for early detection.

Indexed as

Chromosome AberrationsAdenocarcinomaAdultAgedBarrett EsophagusBiopsyCase-Control StudiesChromosomal InstabilityDisease ProgressionEndoscopyEsophageal NeoplasmsFemaleGenome, HumanHumansLongitudinal StudiesLoss of Heterozygosity

Identifiers

PMID24253313
PMCPMC3904552
OpenAlexW2151606858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.